ʻO kā mākou haʻawina nui, ʻo ia ka hoʻomau ʻana i ka hoʻokuʻu ʻana i ka lāʻau lapaʻau e hoʻohui i nā pono o ka chemotherapy a me ka immunotherapy, a no ka manawa mua, ua hui ʻia nā mea ʻelua a hoʻopili ʻia i ka intratumoral therapy ma o ka hana. Hoʻohui ia i ka mālama kūloko a me ka honua, a hoʻonui i ka noʻonoʻo a me ka manawa o ka hana lāʻau ma o ka hoʻokuʻu mau ʻana i nā lāʻau lapaʻau i loko o ka ʻōpū, ʻaʻole wale ia e pāʻani i ka hopena anticancer kūloko o nā lāʻau chemotherapy, akā e noʻonoʻo pū i ka hana o ka immunotherapy systemic, no laila e hoʻoponopono ai i nā hemahema o nā lāʻau lapaʻau ʻē aʻe, e hāʻawi ana i nā manaʻo hou a me nā ala no ka mālama ʻana i ka maʻi maʻi, ʻo ia hoʻi no nā maʻi maʻi waena a me ka holomua, ʻoi aku ka nui o ka hōʻemi ʻana i ka waiwai nui o ka tumor; Loaʻa ka maikaʻi o ka UMPIC therapy i ka hoʻohana ʻana i ka maʻi maʻi ma ke ʻano he kumu antigen a me ka lāʻau lapaʻau autologous, ʻo ia hoʻi i ka laina me ke ʻano hoʻomohala o Personalized Medicine. A noi aku i ka halemai, hapten hui me ka chemotherapy laau no ka hoʻomau hoʻokuʻu 'ana o ka pancreatic maʻi 'aʻai kumu kumu, oiai inducing distal hopena, ke kumu o ia mea e induce immune pane, T-cell pili CD4, CD8, DC, T a me NK, a me B-cell-pili tumor autoantibodies: Antibodies i P53, P16, Cviv. p62, HCC1 a me nā oncogenes ʻē aʻe, ʻo ia ka manawa mua e ʻike ai ua komo ʻo T a me B i ka pane ʻana o ka immune, a ua koho ʻia nā hana lapaʻau o ka hopena distal a ua koho ʻia kēia therapy no "Clinical Operation Guidelines for Interventional Treatment of Advanced Pancreatic Cancer" (Trial) (7th edition) i hui pū ʻia e ka Chinese Anti-Cancerrap Association, ka National Clinical and Medical Research Center no ka National Clinical and Medical Research Center. paʻi ʻia ma Journal of Clinical Radiology, volume 43, helu 19, 2024, 1636-1648.